RGD Peptide PET Scans Outperform Standard Imaging for Detecting Brain Tumors

The researchers conducted a systematic literature search of PubMed, EMBASE, and Cochrane Library through November 2024. They included studies using RGD-based PET tracers in neuro-oncological imaging. Data on demographics, tumor types, imaging protocols, and outcomes were extracted. Study quality was assessed using QUADAS-2, the standard tool for evaluating diagnostic accuracy studies.

Standard FDG-PET scans struggle with brain tumors because healthy brain tissue also has high glucose uptake, making it hard to distinguish tumor from normal tissue. RGD peptide tracers target angiogenesis — the new blood vessel growth that feeds tumors — providing a signal that's much more specific to cancer. This could improve diagnosis, surgical planning, and monitoring of treatment effectiveness for one of the deadliest cancer types.

Peptide-based molecular imaging is an expanding field that uses small peptide tracers to visualize specific biological processes in living patients. RGD peptides targeting integrins are among the most studied peptide imaging agents, with applications beyond brain tumors in breast cancer, head and neck cancer, and cardiovascular disease. This review adds to evidence that peptide PET tracers can complement or surpass traditional metabolic imaging, moving toward more precise, biology-driven cancer diagnosis.

Only 8 studies with 112 total patients were included — a small evidence base. Few studies included histopathological validation to confirm that tracer uptake truly reflected integrin expression. RGD PET tracers don't cross the blood-brain barrier, raising questions about whether some of the signal comes from nonspecific accumulation where the barrier is disrupted by the tumor rather than specific integrin binding. No randomized controlled trials were available.